在儿科头痛的进展
Richard N Miller1, Monica E Kim1, Muhammed Talha Gunduz1
1Department of Pediatrics.
Current opinion in pediatrics
|October 14, 2024
概括
儿科头痛的最新进展包括更新的诊断标准和有效的治疗方法. 像甲胺毒素A和鼻内苏马特里普坦这样的疗法在治疗儿科头痛综合征方面表现有前途.
科学领域:
- 儿科神经学 儿科神经学
- 头痛 医学 医学 医学
- 临床研究 临床研究
背景情况:
- 儿童的初级头痛障碍需要更新理解.
- 国际头痛疾病分类第三版 (ICHD-3) 标准正在完善.
- 儿科头痛管理需要基于证据的治疗更新.
研究的目的:
- 为了回顾儿科头痛的最新进展.
- 更新临床医生关于当前的儿科头痛研究和治疗结果.
主要方法:
- 对比儿科头痛症状与ICHD-3标准的近期研究的综述.
- 对各种儿科头痛干预措施的治疗结果的分析.
- 评估新的治疗方法,包括药物和毒素治疗.
主要成果:
- 主要刺痛头痛的持续时间可能超过之前的估计.
- 持续的创伤后和新的每日持续性头痛与偏头痛有共同的特征.
- 生活方式的改善与头痛结果没有直接关联,尽管总体上有所改善.
- 无毒毒素A和无毒毒素A注射显示显著降低头痛得分,副作用最小.
- 鼻内苏马特里普坦在紧急情况下有效降低疼痛评分,可能降低成本和停留时间.
结论:
- 儿科头痛综合征表现出不断变化的症状和持续时间特征.
- 毒素A和毒素A注射是耐受良好且有效的.
- 在急诊室内注射鼻腔苏马特里普坦是一种可行的和有效的治疗选择,用于儿科头痛.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
Pharmacokinetics in Pediatric Patients: Drug Distribution
558
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
558
Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413
Increased Intracranial Pressure l: Introduction
30
Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component...
30
Increased Intracranial Pressure ll: Pathophysiology
39
Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins...
39


